A process for the preparation of a rapidly disintegrating tablet having a disintegration time of at most 15 minutes for the peroral administration of a dry extract from the leaves of Ginkgo biloba and having a total weight of the tablet between 150 mg and 300 mg per 100 mg of the contained ginkgo extract, comprising (a) a first process step in which the ginkgo extract is mixed with 6.94 mg to 27.78 mg of binder per 100 mg of ginkgo extract contained, with 5.56 mg to 22.22 mg of disintegration accelerator per 100 mg of ginkgo extract contained, with 1.11 mg to 4.44 mg of flow regulating agent per 100 mg of ginkgo extract contained, and with 0.28 mg to 1.11 mg of mold release agent per 100 mg of ginkgo extract contained, and then compacted and comminuted to obtain concentrated granules, and (b) a second process step in which the concentrated granules obtained in step (a) are mixed with further 22.78 mg to 91.11 mg of binder per 100 mg of ginkgo extract contained, with further 11.11 mg to 44.44 mg of disintegration accelerator per 100 mg of ginkgo extract contained, with further 0.56 mg to 2.22 mg of flow regulating agent per 100 mg of the ginkgo extract contained and with further 1.67 mg to 6.67 mg of mold release agent per 100 mg of the ginkgo extract contained and pressed into tablets, wherein the total amount of excipients in step (a) is from 13.89 mg to 55.56 mg per 100 mg of ginkgo extract contained and in step (b) is from 36.11 mg to 144.44 mg per 100 mg of ginkgo extract contained; and wherein the binder in step (a) and in step (b) is microcrystalline cellulose, the disintegration accelerator in step (a) and in step (b) is independently selected from croscarmellose sodium, carboxymethyl starch sodium, crospovidone or sodium starch glycolate, the flow control agent in step (a) and in step (b) is independently selected from highly dispersed silica or precipitated silica, and the mold release agent in step (a) and in step (b) is independently selected from magnesium stearate, stearic acid, behenic acid, sodium stearyl fumarate, glycerol dibehenate, calcium behenate or fumaric acid. (a) a first process step in which the ginkgo extract is mixed with 6.94 mg to 27.78 mg of binder per 100 mg of ginkgo extract contained, with 5.56 mg to 22.22 mg of disintegration accelerator per 100 mg of ginkgo extract contained, with 1.11 mg to 4.44 mg of flow regulating agent per 100 mg of ginkgo extract contained, and with 0.28 mg to 1.11 mg of mold release agent per 100 mg of ginkgo extract contained, and then compacted and comminuted to obtain concentrated granules, and (b) a second process step in which the concentrated granules obtained in step (a) are mixed with further 22.78 mg to 91.11 mg of binder per 100 mg of ginkgo extract contained, with further 11.11 mg to 44.44 mg of disintegration accelerator per 100 mg of ginkgo extract contained, with further 0.56 mg to 2.22 mg of flow regulating agent per 100 mg of the ginkgo extract contained and with further 1.67 mg to 6.67 mg of mold release agent per 100 mg of the ginkgo extract contained and pressed into tablets, wherein the total amount of excipients in step (a) is from 13.89 mg to 55.56 mg per 100 mg of ginkgo extract contained and in step (b) is from 36.11 mg to 144.44 mg per 100 mg of ginkgo extract contained; and wherein the binder in step (a) and in step (b) is microcrystalline cellulose, the disintegration accelerator in step (a) and in step (b) is independently selected from croscarmellose sodium, carboxymethyl starch sodium, crospovidone or sodium starch glycolate, the flow control agent in step (a) and in step (b) is independently selected from highly dispersed silica or precipitated silica, and the mold release agent in step (a) and in step (b) is independently selected from magnesium stearate, stearic acid, behenic acid, sodium stearyl fumarate, glycerol dibehenate, calcium behenate or fumaric acid.